Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3030% below fair value
$6.08+0.17 (+2.88%)
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
Bolt Biotherapeutics cash
Cash and short-term investments held at the end of each period.
Bolt Biotherapeutics's cash was $18.10M at Jun 30, 2026. For fiscal 2025 it was $31.80M, down 54.7% from the year before. The highest annual figure on record is $192.80M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.80M | -54.7% |
| FY2024 | Dec 31, 2024 | $70.20M | -45.4% |
| FY2023 | Dec 31, 2023 | $128.60M | -33.3% |
| FY2022 | Dec 31, 2022 | $192.80M | +3.5% |
| FY2021 | Dec 31, 2021 | $186.22M | +715.4% |
| FY2020 | Dec 31, 2020 | $22.84M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.10M | -62.7% |
| Q1 FY2026 | Mar 31, 2026 | $23.90M | -58.8% |
| Q4 FY2025 | Dec 31, 2025 | $31.80M | -54.7% |
| Q3 FY2025 | Sep 30, 2025 | $38.80M | -54.0% |
| Q2 FY2025 | Jun 30, 2025 | $48.50M | -50.3% |
| Q1 FY2025 | Mar 31, 2025 | $58.00M | -48.6% |
| Q4 FY2024 | Dec 31, 2024 | $70.20M | -45.4% |
| Q3 FY2024 | Sep 30, 2024 | $84.40M | -40.3% |
| Q2 FY2024 | Jun 30, 2024 | $97.50M | -37.9% |
| Q1 FY2024 | Mar 31, 2024 | $112.80M | -34.0% |
| Q4 FY2023 | Dec 31, 2023 | $128.60M | -33.3% |
| Q3 FY2023 | Sep 30, 2023 | $141.40M | -32.5% |
| Q2 FY2023 | Jun 30, 2023 | $157.10M | -10.9% |
| Q1 FY2023 | Mar 31, 2023 | $171.00M | -10.4% |
| Q4 FY2022 | Dec 31, 2022 | $192.80M | +3.5% |
| Q3 FY2022 | Sep 30, 2022 | $209.60M | -1.5% |
| Q2 FY2022 | Jun 30, 2022 | $176.34M | -28.0% |
| Q1 FY2022 | Mar 31, 2022 | $190.90M | -28.4% |
| Q4 FY2021 | Dec 31, 2021 | $186.22M | +715.4% |
| Q3 FY2021 | Sep 30, 2021 | $212.89M | +1096.5% |
| Q2 FY2021 | Jun 30, 2021 | $244.99M | +440.7% |
| Q1 FY2021 | Mar 31, 2021 | $266.67M | +2196.1% |
| Q4 FY2020 | Dec 31, 2020 | $22.84M | – |
| Q3 FY2020 | Sep 30, 2020 | $17.79M | – |
| Q2 FY2020 | Jun 30, 2020 | $45.31M | – |
| Q1 FY2020 | Mar 31, 2020 | $11.61M | – |
See a number that looks wrong?